$BGNE with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $BGNE after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 66.67%.
BeOne Medicines Ltd. Class A
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.32 CNY
−4.64 B CNY
27.42 B CNY
114.76 M
About BeOne Medicines Ltd. Class A
Sector
Industry
CEO
John V. Oyler
Website
Headquarters
Basel
Founded
2010
Identifiers
2
ISINCNE100005XT6
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Related stocks
$BGNE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BGNE after a Negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 80%.
$BGNE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BGNE after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 100%.
#6160 pull-back and hits support line $213.6 Hi Everybody
#6160 pull-back and hits support line $213.6, expects to test the BLUE LINES, and stops if closes below the RED line.
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA BGNE: BeiGene, Ltd.
2021-07-29 20:00:00
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
BGNE short above 260$, target price 161$, about Mar 9, 2021.BGNE short above 260$, target price 161$, about Mar 9, 2021.
Similar pattern of Aug 8, 2018.
Wait BGNE price reached 161$, start building long position.
It's not a good idea holding BGNE under 270$~260$
Long stop-Loss price : 259$
Short stop-loss price : 284$
BGNE: Long strategy after gap overlapWe will trade long in the range $140 - 150 amid to gap overlap. Target will be $190 / 200. (+30% potentially)
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
588030
Bosera SSE Science and Technology Innovation Board 100 Index Exchange Traded Fund UnitsWeight
3.01%
Market value
26.63 M
USD
588220
Penghua SSE Science and Technology Innovation Board 100 Index Exchange Traded Fund UnitsWeight
3.03%
Market value
23.13 M
USD
588190
Yinhua SSE Science and Technology Innovation Board 100 Index Exchange Traded Fund UnitsWeight
2.99%
Market value
13.27 M
USD
515120
GF CSI Brand Name Drug Industry Index Exchange Traded Fund UnitsWeight
2.65%
Market value
12.68 M
USD
159837
E Fund CSI Biotechnology Thematic Exchange Traded Fund UnitsWeight
3.08%
Market value
5.34 M
USD
588120
Guotai SSE Science and Technology Innovation Board 100 Index Exchange Traded Fund UnitsWeight
3.02%
Market value
4.16 M
USD
589630
Guotai SSE Science and Technology Innovation Board Composite Index Exchange Traded Fund UnitsWeight
3.02%
Market value
4.16 M
USD
Explore more ETFs
Frequently Asked Questions
The current price of 688235 is 275.06 CNY — it has decreased by −0.12% in the past 24 hours. Watch BeOne Medicines Ltd. Class A stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange BeOne Medicines Ltd. Class A stocks are traded under the ticker 688235.
688235 stock has risen by 0.26% compared to the previous week, the month change is a −3.65% fall, over the last year BeOne Medicines Ltd. Class A has showed a 72.00% increase.
We've gathered analysts' opinions on BeOne Medicines Ltd. Class A future price: according to them, 688235 price has a max estimate of 376.00 CNY and a min estimate of 320.00 CNY. Watch 688235 chart and read a more detailed BeOne Medicines Ltd. Class A stock forecast: see what analysts think of BeOne Medicines Ltd. Class A and suggest that you do with its stocks.
688235 reached its all-time high on Sep 2, 2025 with the price of 346.00 CNY, and its all-time low was 82.00 CNY and was reached on Apr 27, 2022. View more price dynamics on 688235 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
688235 stock is 1.93% volatile and has beta coefficient of 0.27. Track BeOne Medicines Ltd. Class A stock price on the chart and check out the list of the most volatile stocks — is BeOne Medicines Ltd. Class A there?
Today BeOne Medicines Ltd. Class A has the market capitalization of 424.09 B, it has decreased by −10.63% over the last week.
Yes, you can track BeOne Medicines Ltd. Class A financials in yearly and quarterly reports right on TradingView.
BeOne Medicines Ltd. Class A is going to release the next earnings report on Apr 1, 2026. Keep track of upcoming events with our Earnings Calendar.
688235 earnings for the last quarter are 0.65 CNY per share, whereas the estimation was 0.54 CNY resulting in a 19.83% surprise. The estimated earnings for the next quarter are 0.89 CNY per share. See more details about BeOne Medicines Ltd. Class A earnings.
BeOne Medicines Ltd. Class A revenue for the last quarter amounts to 10.06 B CNY, despite the estimated figure of 9.77 B CNY. In the next quarter, revenue is expected to reach 10.35 B CNY.
688235 net income for the last quarter is 893.54 M CNY, while the quarter before that showed 682.22 M CNY of net income which accounts for 30.97% change. Track more BeOne Medicines Ltd. Class A financial stats to get the full picture.
No, 688235 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2025, the company has 11 K employees. See our rating of the largest employees — is BeOne Medicines Ltd. Class A on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BeOne Medicines Ltd. Class A EBITDA is 2.44 B CNY, and current EBITDA margin is −10.40%. See more stats in BeOne Medicines Ltd. Class A financial statements.
Like other stocks, 688235 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BeOne Medicines Ltd. Class A stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BeOne Medicines Ltd. Class A technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BeOne Medicines Ltd. Class A stock shows the buy signal. See more of BeOne Medicines Ltd. Class A technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.